Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Bonesupport

188.50 SEK

+2.56 %

Less than 1K followers

BONEX

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+2.56 %
-9.64 %
-40.80 %
-29.77 %
-51.27 %
-47.20 %
+122.03 %
+149.34 %
+489.06 %

Bonesupport operates in the medical technology industry and focuses on the development and manufacture of bioceramic implants for bone repair and reconstruction. The company's products are aimed at surgeons and healthcare institutions. The business is global with a primary presence in Europe, North America and Asia. Bonesupport was founded in 1999 and is headquartered in Lund, Sweden.

Read more
Market cap
12.59B SEK
Turnover
64.81M SEK
Revenue
898.73M
EBIT %
18.49 %
P/E
92.4
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24/2
2026

Annual report '25

22/4
2026

Interim report Q1'26

12/5
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release12/3/2025, 9:53 AM

Finansinspektionen: Flaggningsmeddelande i BONESUPPORT HOLDING AB

Bonesupport
Regulatory press release12/2/2025, 7:13 AM

CERAMENT® V ansökan i USA överförs till De Novo-process

Bonesupport
Regulatory press release12/2/2025, 7:13 AM

CERAMENT® V application in the U.S. transferred to the De Novo process

Bonesupport

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release10/31/2025, 3:40 PM

BONESUPPORT HOLDING AB (publ) – Rättelse i Q3 2025 delårsrapport

Bonesupport
Press release10/31/2025, 3:40 PM

BONESUPPORT HOLDING AB (publ) – Correction in Q3 2025 interim report

Bonesupport
Press release10/24/2025, 7:12 AM

Redeye: BONESUPPORT (Q3 Review) - Still just getting started

Bonesupport
Bonesupport, Audiocast, Q3'25
Webcast10/23/2025, 8:00 AM

Bonesupport, Audiocast, Q3'25

Bonesupport
Regulatory press release10/23/2025, 6:00 AM

BONESUPPORT HOLDING AB (publ) – publicerar Q3 2025 delårsrapport

Bonesupport
Regulatory press release10/23/2025, 6:00 AM

BONESUPPORT HOLDING AB (publ) – publishes Q3 2025 Interim report

Bonesupport
Press release10/20/2025, 12:15 PM

Modular Finance IR Consensus: BONESUPPORT – Consensus estimates Q3 2025

Bonesupport
Press release10/16/2025, 6:00 AM

BONESUPPORT HOLDING AB (publ) – Inbjudan till konferenssamtal och webbsändning för delårsrapport Q3 2025

Bonesupport
Press release10/16/2025, 6:00 AM

BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim report Q3 2025

Bonesupport
Press release9/16/2025, 6:50 AM

Inga infektionsrecidiv vid användning av CERAMENT® G vid infekterade höftimplantat

Bonesupport
Press release9/16/2025, 6:50 AM

No infection recurrence when using CERAMENT® G in infected hip implant management

Bonesupport
Press release9/15/2025, 7:40 AM

Starka CERAMENT®-resultat presenterade vid EBJIS

Bonesupport
Press release9/15/2025, 7:40 AM

Strong CERAMENT® Results Presented at EBJIS

Bonesupport
Regulatory press release8/12/2025, 2:51 PM

CMS GODKÄNNER NTAP FÖR CERAMENT® G VID ÖPPNA FRAKTURER - GER SJUKHUSEN YTTERLIGARE ERSÄTTNING FRÅN OCH MED 1 OKTOBER 2025

Bonesupport
Regulatory press release8/12/2025, 2:51 PM

CMS APPROVES NTAP FOR CERAMENT® G IN OPEN FRACTURES, PROVIDING ADDITIONAL HOSPITAL REIMBURSEMENT STARTING OCTOBER 1, 2025

Bonesupport
Press release7/30/2025, 7:42 AM

MEDDELAD INSYNSHANDEL

Bonesupport
Press release7/30/2025, 7:42 AM

ANNOUNCED INSIDER TRADING

Bonesupport
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.